In 2024, Philips Foundation initiated 22 new projects and 5 new impact investments expanding its impact and reach in innovative healthcare delivery to India and South America Celebrating a decade of impact with strong progress towards the Foundation’s 2030 goal to improve access to healthcare for 100 million people in underserved communities a year The [...]
June 5, 2025 (Korea Bizwire) Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), today announced that the exchange ratio for the dividend for the year 2024 is 1 new common share for every 23.6353 existing common shares. This ratio was based on the volume weighted average price on Euronext Amsterdam of May 30, June 2, [...]
June 4, 2025 (Korea Bizwire) Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA) today announced that it will repurchase up to 6 million shares to cover certain of its obligations arising from its long-term incentive plans. At the current share price, the shares represent an amount of up to approximately EUR 125 million. The repurchases will be executed through one or [...]
TEL AVIV, Israel, June 03, 2025 (Korea Bizwire) – Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) (“Teva”) announced today the pricing and early acceptance results of its previously announced tender offers (the “Offers”) to purchase for cash the outstanding notes issued by finance subsidiaries of Teva and guaranteed by Teva of the series described [...]
TEL AVIV, Israel, June 03, 2025 (Korea Bizwire) — Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) (“Teva”) announced today the early tender results in connection with its previously announced tender offers (the “Offers”) as specified below for the following series of notes issued by finance subsidiaries of Teva and guaranteed by Teva: USD 3.150% [...]
Ad-hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules WYOST® (denosumab-bbdz) and Jubbonti® (denosumab-bbdz) are first and only FDA-approved interchangeable denosumab biosimilars available in US Improves access for patients living with osteoporosis and cancer-related skeletal events in US and enhances US biosimilar portfolio Builds on established experience and leadership in oncology and immunology [...]
More than half of residents with tardive dyskinesia (TD) residing in long-term care (LTC) settings do not receive standard of care treatment, and one-quarter are left untreated LTC residents are often given a broader diagnosis of extrapyramidal syndrome, which can lead to incorrect treatment options for TD Teva is committed to continuing to advance research [...]
Real-world claims studies evaluating UZEDY® (risperidone) also show improved adherence and persistence rates, fewer inpatient, outpatient and emergency department (ED) visits versus second-generation daily oral options Latest Phase 3 SOLARIS data show no suspected or confirmed PDSS events with TEV-’749 after more than 3,400 subcutaneous injections in study participants to date As a leader in neuroscience, Teva [...]
European culinary excellence arrives in Korea, embracing modern lifestyles and sustainable values SEOUL, South Korea, May 30, 2025 (Korea Bizwire) — The “EU Good Food – Good Life” campaign, funded by the European Union, was officially launched in South Korea, marking the start of its public communication activities in the country. This three-year initiative (2024–2027), co-funded [...]
Zanidatamab is the first and only dual HER2-targeted bispecific antibody approved for HER2+ biliary tract cancer in China; conditional approval based on the results of the HERIZON-BTC-01 clinical study $20 million milestone payment to be received from BeOne Medicines; Zymeworks remains eligible to receive up to $144 million in additional development and commercial milestones VANCOUVER, [...]